Homocysteine and cardiovascular disease: cause or effect?
Top Cited Papers
Open Access
- 1 August 2000
- journal article
- review article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 72 (2) , 315-323
- https://doi.org/10.1093/ajcn/72.2.315
Abstract
Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200–300 μmol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (>15 μmol/L) occurs in ≈20–30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.Keywords
This publication has 129 references indexed in Scilit:
- Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitusKidney International, 1999
- Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuriaKidney International, 1999
- A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians.Journal of the American College of Nutrition, 1996
- Higher Plasma Homocyst(e)ine and Increased Susceptibility to Adverse Effects of Low Folate in Early Familial Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folateThe American Journal of Cardiology, 1995
- Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentrationAtherosclerosis, 1995
- Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patientsThe American Journal of Cardiology, 1995
- Heterozygosity for Homocystinuria in Premature Peripheral and Cerebral Occlusive Arterial DiseaseNew England Journal of Medicine, 1985
- Cerebral thrombosis in a patient with homocystinuriaThe Journal of Pediatrics, 1969
- HomocystinuriaThe Journal of Pediatrics, 1965